HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $14 to $18.
William Penn Q2 EPS $0.08 Misses $0.09 Estimate
William Penn (NASDAQ:WMPN) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year.
